Answers are grounded in this paper and cite their sources.
The American Society of Hematology (ASH) adopted a site-level quality measure (QM) quantifying differences in median time to first pain medication between adult sickle cell disease (SCD) vaso-occlusive episodes (VOE) and renal colic in emergency departments (EDs). Large-scale evaluation of this QM is lacking. We analyzed records from 103 U.S. adult EDs using 2019-2025 Epic Cosmos electronic health record data. Included sites had at least 100 SCD VOE and 100 renal colic encounters. The QM was calculated per site as median time to first pain medication for SCD VOE minus median time for renal colic, in minutes. Sites were categorized as SCD-Advantaged (<−10 min), Equivalent (±10 min), or SCD-Disadvantaged (>+10 min). Spearman correlations assessed relationships between QM scores and site-level SCD encounter volume, ED length of stay (LOS), and hospital admission rates. Across 103 adult EDs, 436,692 SCD VOE and 5,596,964 renal colic encounters were analyzed. QM scores ranged from −145 to +91 minutes (median: +4). Most sites (56.3%) demonstrated equivalent first-analgesia timeliness; 15.5% provided faster analgesia for SCD VOE, while 28.2% showed delays for SCD VOE (>+10 minutes, median gap: +19 min). QM scores were not associated with SCD encounter volume (p = 0.42), ED LOS (p = 0.94), or hospital admission rate (p = 0.34). We found no major differences in acute pain-care timeliness for SCD versus renal colic across most sites; however, several EDs demonstrated opportunities for improvement. These findings establish the first national baseline for the ASH QM.
No takes yet. Share an insight, caveat, or question.
Gwarzo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: